Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The ALPINE study (NCT03734016) investigated zanubrutinib vs. ibrutinib in relapsed/refractory chronic lymphocytic leukemia (CLL). Here, Constantine Tam, MD, FRACP, FRCPA, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the results thus far from the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.